Clinical Trials
136 trialsEtoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
SCCLG-M5
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
Ruijin Hospital
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL
The First Affiliated Hospital of Soochow University
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
BEAM
Swedish Medical Center
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Shengjing Hospital
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
LanZhou University
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
PETHEMA Foundation
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
Shengjing Hospital
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years
PETHEMA Foundation
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
PETHEMA Foundation
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
PALG-AML1/2016
Polish Adult Leukemia Group
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
First Affiliated Hospital Xi'an Jiaotong University
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
PETHEMA Foundation
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
Sun Yat-sen University
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Chinese PLA General Hospital
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Shengjing Hospital
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The First Affiliated Hospital of Soochow University
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
Sun Yat-sen University
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
Sun Yat-sen University
Interfant06
Dutch Childhood Oncology Group
TRANSATRA
University Hospital Freiburg
RADICAL
Asan Medical Center
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Nanfang Hospital, Southern Medical University
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Nanfang Hospital, Southern Medical University
AML
Mateon Therapeutics
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
IVAM
Asan Medical Center
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
Shanghai Tong Ren Hospital
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
Sun Yat-sen University